Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $15.16 Analyst target: $37.00 Upside: 144.06%
Mesoblast Limited, a biopharmaceutical company, develops and markets allogeneic cellular drugs. The company is headquartered in Melbourne, Australia.
See the full interactive analysis & chart →Informational only — not investment advice.